Evidence map›Paper›PMID 34115754›Full record

ArticlePLoS neglected tropical diseases2021

Feasibility of a dried blood spot strategy for serological screening and surveillance to monitor elimination of Human African Trypanosomiasis in the Democratic Republic of the Congo.

Raquel Inocencio da Luz, Delphin Mavinga Phanzu, Oscar N'lemvo Kiabanzawoko, Eric Miaka, Paul Verlé, Anja De Weggheleire, Philippe Büscher, Epco Hasker, Marleen Boelaert

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Two-Year Follow-Up ofDiagnostics (Basel, Switzerland) · 2022
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Raquel Inocencio da LuzInstitute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0002-2870-0311
Delphin Mavinga PhanzuCentre de Recherche en Santé de Kimpese, Kimpese, Democratic Republic of the Congo.ORCID 0000-0001-7714-6831
Oscar N'lemvo KiabanzawokoCentre de Recherche en Santé de Kimpese, Kimpese, Democratic Republic of the Congo.
Eric MiakaNational Sleeping Sickness Control Program, Kinshasa, Democratic Republic of the Congo.
Paul VerléInstitute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0002-7252-5872
Anja De WeggheleireInstitute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0001-9377-4766
Philippe BüscherInstitute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0002-1926-7472
Epco HaskerInstitute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0002-3154-0419
Marleen BoelaertInstitute of Tropical Medicine, Antwerp, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, the number of reported Human African Trypanosomiasis (HAT) cases caused by Trypanosoma brucei (T.b.) gambiense has been markedly declining, and the goal of 'elimination as a public health problem' is within reach. For the next stage, i.e. interruption of HAT transmission by 2030, intensive screening and surveillance will need to be maintained, but with tools and strategies more efficiently tailored to the very low prevalence. We assessed the sequential use of ELISA and Immune Trypanolysis (ITL) on dried blood spot (DBS) samples as an alternative to the traditional HAT field testing and confirmation approach. A cross-sectional study was conducted in HAT endemic and previously endemic zones in Kongo Central province, and a non-endemic zone in Haut Katanga province in the Democratic Republic of the Congo (DRC). Door-to-door visits were performed to collect dried blood spot (DBS) samples on filter paper. ELISA/T.b. gambiense was conducted followed by ITL for those testing positive by ELISA and in a subset of ELISA negatives. In total, 11,642 participants were enrolled. Of these, 11,535 DBS were collected and stored in appropriate condition for ELISA testing. Ninety-seven DBS samples tested positive on ELISA. In the endemic zone, ELISA positivity was 1.34% (95%CI: 1.04-1.64). In the previously endemic zone and non-endemic zone, ELISA positivity was 0.34% (95% CI: 0.13-0.55) and 0.37% (95% CI: 0.15-0.60) respectively. Among the ELISA positives, only two samples had a positive ITL result, both from the endemic zone. One of those was from a former HAT patient treated in 2008 and the other from an individual who unfortunately had deceased prior to the follow-up visit. Our study showed that a surveillance strategy, based on DBS samples and centralized testing with retracing of patients if needed, is feasible in DRC. ELISA seems well suited as initial test with a similar positivity rate as traditional screening tests, but ITL remains complex. Alternatives for the latter, also analyzable on DBS, should be further explored.

Indexed as

Disease EradicationAdolescentAdultAgedAged, 80 and overChildChild, PreschoolCross-Sectional StudiesDemocratic Republic of the CongoDried Blood Spot TestingFeasibility StudiesFemaleHumansInfantMaleMiddle AgedTrypanocidal Agents

Identifiers

PMID34115754
PMCPMC8195376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.